You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Mallinckrodt
Baxter

Last Updated: April 10, 2020

DrugPatentWatch Database Preview

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Olmesartan Medoxomil And Hydrochlorothiazide, and when can generic versions of Olmesartan Medoxomil And Hydrochlorothiazide launch?

Olmesartan Medoxomil And Hydrochlorothiazide is a drug marketed by Accord Hlthcare, Alembic Pharms Ltd, Aurobindo Pharma Ltd, Mylan, Prinston Inc, Teva Pharms Usa, Torrent, and Umedica Labs Pvt Ltd. and is included in eight NDAs.

The generic ingredient in OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; olmesartan medoxomil. There are thirty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.

Summary for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Drug patent expirations by year for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Recent Clinical Trials for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Altasciences Company Inc.Phase 1
Pharmtechnology LLCPhase 1
Daiichi Sankyo Korea Co., Ltd.Phase 3

See all OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE clinical trials

Pharmacology for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

US Patents and Regulatory Information for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 209281-001 Feb 7, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Pharms Usa OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200532-003 Apr 24, 2017 DISCN No No   Start Trial   Start Trial   Start Trial
Umedica Labs Pvt Ltd OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 208847-002 Sep 17, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.